Table 1.
Results and characteristics of patients with hepatocellular carcinoma (HCC)
| Patient | Etiology | Non-tumor tissue | Tumor tissue | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Fibrosis | Methylight | MSP | IRS | Methylight | ||||||
| Result | PMR | Result | PMR | MSP | IRS | |||||
| HCC1 | alcoholic | 6 | neg | 0.08 | neg | 4 | neg | 0.14 | neg | 0 |
| HCC2 | cryptogenic | 2 | neg | 0.04 | neg | 2 | neg | 3.73 | pos | 0 |
| HCC3 | HH | 3 | neg | 0.01 | pos | 2 | neg | 0.04 | pos | 0 |
| HCC4 | alcoholic | 3 | neg | 0.01 | pos | 0 | neg | 0.01 | neg | 0 |
| HCC5 | alcoholic | 4 | neg | 1.39 | neg | 3 | pos | 100 | neg | 0 |
| HCC6 | cryptogenic | 6 | neg | 0.19 | pos | 4 | pos | 14.64 | pos | 0 |
| HCC7 | cryptogenic | 2 | neg | 0.01 | neg | 0 | neg | 0.41 | pos | 0 |
| HCC8 | alcoholic | 2 | neg | 0.01 | pos | 0 | pos | 10.43 | neg | 0 |
| HCC9 | cryptogenic | 5 | neg | 0.11 | pos | 4 | pos | 39.81 | pos | 0 |
| HCC10 | alcoholic* | 4 | neg | 0.01 | neg | 2 | pos | 11.82 | pos | 4 |
| HCC11 | cryptogenic | 2 | neg | 0.05 | neg | 2 | neg | 0.01 | neg | 3 |
| HCC12 | alcoholic | 4 | pos | 22.44 | neg | 2 | pos | 26.86 | pos | 0 |
| HCC13 | alcoholic | 4 | neg | 0.3 | neg | 0 | pos | 31.62 | pos | 0 |
| HCC14 | cryptogenic | 1 | neg | 0.69 | neg | 3 | pos | 52.09 | pos | 0 |
| HCC15 | cryptogenic | 2 | neg | 0.01 | nd | 0 | pos | 21.43 | nd | 0 |
| HCC16 | alcoholic | 6 | neg | 0.71 | pos | 2 | pos | 100 | pos | 0 |
| HCC17 | cryptogenic | 2 | neg | 0.12 | nd | 4 | pos | 22.11 | nd | 0 |
| HCC18 | cryptogenic | 4 | neg | 0.15 | neg | 0 | pos | 41.06 | pos | 0 |
| HCC19 | alcoholic | 6 | neg | 0.01 | neg | 0 | pos | 88.81 | pos | 0 |
| HCC20 | cryptogenic | 2 | neg | 0.01 | neg | 2 | neg | 0.03 | neg | 0 |
| HCC21 | cryptogenic | 3 | neg | 0.01 | pos | 0 | pos | 24.23 | pos | 2 |
| HCC22 | HBV/HCV | 6 | neg | 1.46 | neg | 0 | neg | 1.92 | neg | 0 |
| HCC23 | HCV | 1 | neg | 0.5 | neg | 0 | pos | 50.96 | pos | 0 |
| HCC24 | HCV | 6 | neg | 0.86 | neg | 0 | pos | 7.91 | pos | 0 |
| HCC25 | HCV | 6 | neg | 0.07 | neg | 0 | neg | 1.19 | neg | 0 |
| HCC26 | HCV | 3 | neg | 0.19 | pos | 0 | pos | 74.13 | pos | 0 |
| HCC27 | HCV | 6 | neg | 0.82 | neg | 0 | neg | 3.59 | pos | 0 |
| HCC28 | HCV | 2 | neg | 2.31 | neg | 0 | pos | 11.14 | pos | 0 |
| HCC29 | HCV | 6 | neg | 0.09 | neg | 0 | pos | 30.36 | pos | 0 |
| HCC30 | HCV | 3 | neg | 0.19 | neg | 2 | pos | 19.78 | pos | 0 |
| HCC31 | HCV | 5 | neg | 0.11 | neg | 0 | pos | 14.12 | pos | 4 |
| HCC32 | crpytogenic | 2 | neg | 0.01 | nd | nd | pos | 88.22 | nd | nd |
| HCC33 | cryptogenic | 6 | neg | 0.37 | neg | nd | pos | 100 | neg | nd |
| HCC34 | HCV | 6 | nd | nd | nd | 0 | nd | nd | nd | 0 |
| HCC35 | HCV | 6 | nd | nd | nd | 3 | nd | nd | nd | 0 |
| HCC36 | HCV/alcoholic | 6 | nd | nd | nd | 0 | nd | nd | nd | 0 |
| HCC37 | HCV | 5 | nd | nd | nd | 3 | nd | nd | nd | 0 |
| HCC38 | HCV | 6 | nd | nd | nd | 3 | nd | nd | nd | 0 |
| HCC39 | HCV | 5 | nd | nd | nd | 2 | nd | nd | nd | 0 |
| HCC40 | HCV | 5 | nd | nd | nd | 6 | nd | nd | nd | 5 |
| HCC41 | HCV/alcoholic | 3 | nd | nd | nd | 2 | nd | nd | nd | 0 |
| HCC42 | HCV/alcoholic | 6 | nd | nd | nd | 1 | nd | nd | nd | 0 |
| HCC43 | HCV/alcoholic | na | nd | nd | nd | nd | nd | nd | nd | 0 |
| HCC44 | HCV | na | nd | nd | nd | nd | nd | nd | nd | 0 |
| HCC45 | HCV | na | nd | nd | nd | nd | nd | nd | nd | 0 |
| HCC46 | HCV | na | nd | nd | nd | nd | nd | nd | nd | 0 |
| HCC47 | HCV | na | nd | nd | nd | nd | nd | nd | nd | 0 |
| HCC48 | HCV | na | nd | nd | nd | nd | nd | nd | nd | 0 |
HCC, hepatocellular carcinoma; PMR, percentage of methylated reference (%); MSP, methylation specific PCR;
IRS = Immunoreactivity score, nd, not done; na, not available; AFP, alfa fetoprotein; * the tumor was considered as a mixed form of HCC and CCC; HBV, hepatitis B virus; HCV, hepatitis C virus;